• OPEN AN ACCOUNT
Indian Indices
Nifty
24,426.85 -74.05
(-0.30%)
Sensex
79,809.65 -270.92
( -0.34%)
Bank Nifty
53,655.65 -164.70
( -0.31%)
Nifty IT
35,181.25 -307.50
( -0.87%)
Global Indices
Nasdaq
45,661.67 75.43
(0.17%)
Dow Jones
6,523.31 20.91
(0.32%)
Hang Seng
42,764.54 -64.25
(-0.15%)
Nikkei 225
9,216.82 -38.68
(-0.42%)
Forex
USD-INR
87.60 -0.05
(-0.06%)
EUR-INR
102.16 0.14
(0.13%)
GBP-INR
118.33 0.25
(0.21%)
JPY-INR
0.60 0.00
(0.24%)

EQUITY - MARKET SCREENER

Tirupati Starch & Chemicals Ltd
Industry :  Miscellaneous
BSE Code
ISIN Demat
Book Value()
524582
INE314D01011
63.3441663
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
15.6
172.61
EPS(TTM)
Face Value()
Div & Yield %
11.54
10
0
 

arrow greentech ltd
Divis Lab gains as broker reiterates buy call
Aug 22,2025
The brokerage downplayed concerns over Eli Lilly’s oral GLP-1 candidate Orforglipron and generic risks to Novartis’ heart drug Entresto, which contributes about 20% of Divi’s consolidated revenue. It expects Divi’s to remain a key API supplier, supported by a healthy order pipeline and rising demand in peptides, making the recent stock weakness a buying opportunity.

Over the past month, the stock has fallen 7.08% compared with a 0.84% decline in the Sensex.

Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. The company's consolidated net profit rose 26.74% to Rs 545 crore while net sales rose 13.79% to Rs 2410 crore in Q1 June 2025 over Q1 June 2024.